{"transactions":[{"id":865345,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T21:10:13.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":false,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001957554-26-000011","document":"form4-03032026_040301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000011/form4-03032026_040301.xml","form_type":"4"}},{"id":865344,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:10:13.000Z","date":"2026-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":677,"price":2.87,"value":1942.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":187453,"source":{"system":"sec-edgar","filing":"0001957554-26-000011","document":"form4-03032026_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000011/form4-03032026_040301.xml","form_type":"4"}},{"id":865343,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:10:13.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":true,"shares":2375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":188130,"source":{"system":"sec-edgar","filing":"0001957554-26-000011","document":"form4-03032026_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000011/form4-03032026_040301.xml","form_type":"4"}},{"id":915782,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T23:00:49.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":346800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":346800,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":346800},"source":{"system":"sec-edgar","filing":"0001957554-26-000009","document":"form4-02062026_110245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000009/form4-02062026_110245.xml","form_type":"4"}},{"id":915781,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T23:00:49.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":99100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":99100,"derivative":{"underlying":"Common Stock","underlying_shares":99100},"source":{"system":"sec-edgar","filing":"0001957554-26-000009","document":"form4-02062026_110245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000009/form4-02062026_110245.xml","form_type":"4"}},{"id":917409,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T21:41:46.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":22025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":66075,"derivative":{"underlying":"Common Stock","underlying_shares":22025},"source":{"system":"sec-edgar","filing":"0001957554-26-000007","document":"form4-02052026_090243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000007/form4-02052026_090243.xml","form_type":"4"}},{"id":917408,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T21:41:46.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":6449,"price":3.47,"value":22378.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":185755,"source":{"system":"sec-edgar","filing":"0001957554-26-000007","document":"form4-02052026_090243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000007/form4-02052026_090243.xml","form_type":"4"}},{"id":917407,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T21:41:46.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":22025,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":192204,"source":{"system":"sec-edgar","filing":"0001957554-26-000007","document":"form4-02052026_090243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000007/form4-02052026_090243.xml","form_type":"4"}},{"id":921140,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:36:49.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":29500,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001957554-26-000005","document":"form4-02032026_100245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000005/form4-02032026_100245.xml","form_type":"4"}},{"id":921139,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T22:36:49.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4984,"price":3.51,"value":17493.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":170179,"source":{"system":"sec-edgar","filing":"0001957554-26-000005","document":"form4-02032026_100245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000005/form4-02032026_100245.xml","form_type":"4"}},{"id":921138,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T22:36:49.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":175163,"source":{"system":"sec-edgar","filing":"0001957554-26-000005","document":"form4-02032026_100245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000005/form4-02032026_100245.xml","form_type":"4"}},{"id":950262,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":13600,"derivative":{"underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950261,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950260,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:27:39.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950259,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":4461,"price":2.88,"value":12847.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":160413,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950258,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":13200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":164874,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950257,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2250,"price":3.01,"value":6772.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":151674,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950256,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":153924,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950255,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":19934,"price":3.01,"value":60001.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":146424,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950254,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":166358,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":1226588,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T21:15:22.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."}],"balance_after":2375,"derivative":{"underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001415889-25-006494","document":"form4-03042025_040308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006494/form4-03042025_040308.xml","form_type":"4"}},{"id":1226587,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T21:15:22.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001415889-25-006494","document":"form4-03042025_040308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006494/form4-03042025_040308.xml","form_type":"4"}},{"id":1226586,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:15:22.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":727,"price":1.99,"value":1446.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":92608,"source":{"system":"sec-edgar","filing":"0001415889-25-006494","document":"form4-03042025_040308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006494/form4-03042025_040308.xml","form_type":"4"}},{"id":1226585,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:15:22.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":2375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":93335,"source":{"system":"sec-edgar","filing":"0001415889-25-006494","document":"form4-03042025_040308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006494/form4-03042025_040308.xml","form_type":"4"}},{"id":1226584,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:15:22.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":90960,"source":{"system":"sec-edgar","filing":"0001415889-25-006494","document":"form4-03042025_040308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925006494/form4-03042025_040308.xml","form_type":"4"}},{"id":1283833,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-04T21:15:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":308200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":308200,"derivative":{"exercise_price":2.4,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":308200},"source":{"system":"sec-edgar","filing":"0001415889-25-002939","document":"form4-02042025_040204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002939/form4-02042025_040204.xml","form_type":"4"}},{"id":1283832,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T21:15:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":88100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":88100,"derivative":{"underlying":"Common Stock","underlying_shares":88100},"source":{"system":"sec-edgar","filing":"0001415889-25-002939","document":"form4-02042025_040204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002939/form4-02042025_040204.xml","form_type":"4"}},{"id":1283831,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T21:15:09.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":44250,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001415889-25-002939","document":"form4-02042025_040204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002939/form4-02042025_040204.xml","form_type":"4"}},{"id":1283830,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T21:15:09.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":5816,"price":2.48,"value":14423.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":89860,"source":{"system":"sec-edgar","filing":"0001415889-25-002939","document":"form4-02042025_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002939/form4-02042025_040204.xml","form_type":"4"}},{"id":1283829,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T21:15:09.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":95676,"source":{"system":"sec-edgar","filing":"0001415889-25-002939","document":"form4-02042025_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925002939/form4-02042025_040204.xml","form_type":"4"}},{"id":1313676,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":false,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":26800,"derivative":{"underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313675,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313674,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313673,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T23:25:10.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":73750,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313672,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":5059,"price":2.48,"value":12546.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":80926,"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313671,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":true,"shares":13200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":85985,"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313670,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2430,"price":2.48,"value":6026.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":72785,"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313669,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:10.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":75215,"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313668,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:10.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":30732,"price":2.48,"value":76215.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":67715,"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1313667,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T23:25:10.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":98447,"source":{"system":"sec-edgar","filing":"0001415889-25-000623","document":"form4-01032025_060106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925000623/form4-01032025_060106.xml","form_type":"4"}},{"id":1415243,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-04T23:52:56.000Z","date":"2024-09-01","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vested on September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vested on September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001415889-24-022825","document":"form4-09042024_100921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924022825/form4-09042024_100921.xml","form_type":"4"}},{"id":1415242,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-04T23:52:56.000Z","date":"2024-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":286,"price":1.18,"value":337.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":24697,"source":{"system":"sec-edgar","filing":"0001415889-24-022825","document":"form4-09042024_100921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924022825/form4-09042024_100921.xml","form_type":"4"}},{"id":1415241,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-04T23:52:56.000Z","date":"2024-09-01","kind":"exercise","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":24983,"source":{"system":"sec-edgar","filing":"0001415889-24-022825","document":"form4-09042024_100921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924022825/form4-09042024_100921.xml","form_type":"4"}},{"id":1594276,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-02","kind":"exercise","planned":false,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024,  subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024,  subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594275,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."}],"balance_after":4750,"derivative":{"underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594274,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":1100,"derivative":{"underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594273,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":427,"price":1.24,"value":529.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":23983,"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594272,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-02","kind":"exercise","planned":false,"acquired":true,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":24410,"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594271,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":677,"price":1.24,"value":839.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":22910,"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594270,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":2375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":23587,"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594269,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":313,"price":1.24,"value":388.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":21212,"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1594268,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T22:02:09.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":21525,"source":{"system":"sec-edgar","filing":"0001209191-24-004397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124004397/doc4.xml","form_type":"4"}},{"id":1658221,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-06T00:27:54.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":147500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":147500,"derivative":{"underlying":"Common Stock","underlying_shares":147500},"source":{"system":"sec-edgar","filing":"0001209191-24-002836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124002836/doc4.xml","form_type":"4"}},{"id":1658220,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-06T00:27:54.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":59000,"derivative":{"underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001209191-24-002836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124002836/doc4.xml","form_type":"4"}},{"id":1658219,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-02-06T00:27:54.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":206500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":206500,"derivative":{"exercise_price":1.2,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":206500},"source":{"system":"sec-edgar","filing":"0001209191-24-002836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124002836/doc4.xml","form_type":"4"}},{"id":1691059,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-03T21:47:44.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-24-000425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124000425/doc4.xml","form_type":"4"}},{"id":1691058,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-03T21:47:44.000Z","date":"2024-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2536,"price":1.05,"value":2662.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":20425,"source":{"system":"sec-edgar","filing":"0001209191-24-000425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124000425/doc4.xml","form_type":"4"}},{"id":1691057,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-03T21:47:44.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":22961,"source":{"system":"sec-edgar","filing":"0001209191-24-000425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919124000425/doc4.xml","form_type":"4"}},{"id":1785618,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-07T20:16:48.000Z","date":"2023-09-06","kind":"purchase","planned":false,"acquired":true,"shares":9490,"price":7.9,"value":74971.0,"ownership":{"direct":true},"balance_after":15461,"source":{"system":"sec-edgar","filing":"0001209191-23-048612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123048612/doc4.xml","form_type":"4"}},{"id":1788796,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-05T21:08:45.000Z","date":"2023-09-01","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1000,"derivative":{"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001209191-23-048199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123048199/doc4.xml","form_type":"4"}},{"id":1788795,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-05T21:08:45.000Z","date":"2023-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":285,"price":7.9,"value":2251.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":5971,"source":{"system":"sec-edgar","filing":"0001209191-23-048199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123048199/doc4.xml","form_type":"4"}},{"id":1788794,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-05T21:08:45.000Z","date":"2023-09-01","kind":"exercise","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":6256,"source":{"system":"sec-edgar","filing":"0001209191-23-048199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123048199/doc4.xml","form_type":"4"}},{"id":1971832,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-02","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1500,"derivative":{"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971831,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":7125,"derivative":{"underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971830,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":2200,"derivative":{"underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971829,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":1475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as\nof the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as\nof the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1475},"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971828,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":894,"price":12.6281,"value":11289.5214,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.47 to $12.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5256,"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971827,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-02","kind":"exercise","acquired":true,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":6150,"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971826,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1000,"price":12.289,"value":12289.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.96 to $12.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4650,"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971825,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":2375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":5650,"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971824,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":1100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":3275,"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":1971823,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:09:46.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":1475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":2175,"source":{"system":"sec-edgar","filing":"0001209191-23-016063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123016063/doc4.xml","form_type":"4"}},{"id":2032184,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T21:55:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-006969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123006969/doc4.xml","form_type":"4"}},{"id":2032183,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-03T21:55:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":105000,"derivative":{"exercise_price":16.97,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-23-006969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123006969/doc4.xml","form_type":"4"}}]}